Cardiff Oncology Inc. (CRDF)
Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer
Cardiff Oncology posted Phase II data for onvansertib in RAS-mutated mCRC, showing a 72% ORR versus 40–45% for standard-of-care. Onvansertib's efficacy, durability, and safety profile suggest it could become a first-line standard-of-care backbone in a $1.2B–$2.5B U.S. market. Despite positive data, CRDF trades near $1.50/share due to small sample size, data immaturity, and anticipated dilution; risk remains high.
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm
Cardiff Oncology (CRDF) remains a single-asset biotech, with its thesis reliant on onvansertib targeting PLK1 in difficult-to-treat cancers. Recent phase 2 CRDF-004 data showed diminished response rates for onvansertib versus earlier readouts, though both doses outperformed control. Cash runway extends into Q1 2027, but future large-scale trials will likely require significant additional funding.
Cardiff Oncology: Preparing For A Defining 2026
Cardiff Oncology is a speculative buy, driven by the potential of onvansertib as a first-in-class PLK1 inhibitor for first-line RAS-mutated mCRC. CRDF's Q1 2026 data readout for onvansertib is a pivotal catalyst, with positive results potentially unlocking blockbuster sales and significant share price appreciation. Key risks include clinical trial execution, capital needs, and heavy reliance on onvansertib as the sole pipeline asset, justifying a conviction rating of 3 out of 5.
Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy
Cardiff Oncology receives a 'Buy' rating, driven by promising clinical data and strategic leadership for long-term investors. CRDF's lead candidate, onvansertib, shows strong efficacy and safety in Phase 2 trials for RAS-mutated metastatic colorectal and triple-negative breast cancers. Despite competition and clinical-stage risks, onvansertib's unique PLK1 inhibition mechanism offers breakthrough potential in multi-billion-dollar cancer markets.
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity
Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans.
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cardiff Oncology: Buying The First-Line Onvansertib Strategy
Cardiff Oncology's onvansertib shows promise as a first-in-class PLK1 inhibitor for first-line RAS-mutated metastatic colorectal cancer, potentially redefining standard-of-care and achieving blockbuster status. Onvansertib's synergy with bevacizumab and promising clinical data support its pivot to first-line treatment, with potential peak global sales of $1.2B to $2B annually. Despite strong prospects, CRDF faces risks including clinical/regulatory hurdles, market competition, and financial challenges, necessitating potential dilutive funding for Phase III trials and commercialization.
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.22 per share a year ago.
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon
Cardiff Oncology's onvansertib shows promising early results in improving response rates for RAS-mutated colorectal cancer, with a critical data update expected by mid-2025. Financially, CRDF has sufficient funds to operate until early 2027 but will face funding challenges by 2026, potentially impacting stock value. The success of onvansertib in first-line metastatic colorectal cancer is crucial, with high upside potential but significant risk if upcoming data disappoints.
